ID   GWL_HUMAN               Reviewed;         879 AA.
AC   Q96GX5; Q5T8D5; Q5T8D7; Q8NCD6; Q96SJ5;
DT   05-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   15-MAR-2017, entry version 149.
DE   RecName: Full=Serine/threonine-protein kinase greatwall;
DE            Short=GW;
DE            Short=GWL;
DE            Short=hGWL;
DE            EC=2.7.11.1;
DE   AltName: Full=Microtubule-associated serine/threonine-protein kinase-like;
DE            Short=MAST-L;
GN   Name=MASTL; Synonyms=GW, GWL, THC2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-370, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-370; SER-657 AND
RP   SER-878, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-293; SER-370; SER-552;
RP   SER-556; THR-722; SER-725; THR-741; SER-875 AND SER-878, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   FUNCTION.
RX   PubMed=19680222; DOI=10.1038/emboj.2009.228;
RA   Vigneron S., Brioudes E., Burgess A., Labbe J.C., Lorca T., Castro A.;
RT   "Greatwall maintains mitosis through regulation of PP2A.";
RL   EMBO J. 28:2786-2793(2009).
RN   [9]
RP   FUNCTION.
RX   PubMed=19793917; DOI=10.1091/mbc.E09-07-0643;
RA   Castilho P.V., Williams B.C., Mochida S., Zhao Y., Goldberg M.L.;
RT   "The M phase kinase Greatwall (Gwl) promotes inactivation of
RT   PP2A/B55delta, a phosphatase directed against CDK phosphosites.";
RL   Mol. Biol. Cell 20:4777-4789(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=20818157; DOI=10.4161/cc.9.17.12832;
RA   Voets E., Wolthuis R.M.F.;
RT   "MASTL is the human orthologue of Greatwall kinase that facilitates
RT   mitotic entry, anaphase and cytokinesis.";
RL   Cell Cycle 9:3591-3601(2010).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=20538976; DOI=10.1073/pnas.0914191107;
RA   Burgess A., Vigneron S., Brioudes E., Labbe J.-C., Lorca T.,
RA   Castro A.;
RT   "Loss of human Greatwall results in G2 arrest and multiple mitotic
RT   defects due to deregulation of the cyclin B-Cdc2/PP2A balance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:12564-12569(2010).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-207; THR-222; SER-370;
RP   SER-631; SER-668; SER-875 AND SER-878, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-72.
RX   PubMed=21164014; DOI=10.1126/science.1197048;
RA   Gharbi-Ayachi A., Labbe J.C., Burgess A., Vigneron S., Strub J.M.,
RA   Brioudes E., Van-Dorsselaer A., Castro A., Lorca T.;
RT   "The substrate of Greatwall kinase, Arpp19, controls mitosis by
RT   inhibiting protein phosphatase 2A.";
RL   Science 330:1673-1677(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-370; SER-453; THR-519;
RP   SER-657 AND SER-878, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   VARIANT THC2 ASP-167, AND FUNCTION.
RX   PubMed=12890928; DOI=10.1159/000071812;
RA   Gandhi M.J., Cummings C.L., Drachman J.G.;
RT   "FLJ14813 missense mutation: a candidate for autosomal dominant
RT   thrombocytopenia on human chromosome 10.";
RL   Hum. Hered. 55:66-70(2003).
RN   [19]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-337; ILE-610 AND ALA-620.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase that plays a key role in M phase
CC       by acting as a regulator of mitosis entry and maintenance. Acts by
CC       promoting the inactivation of protein phosphatase 2A (PP2A) during
CC       M phase: does not directly inhibit PP2A but acts by mediating
CC       phosphorylation and subsequent activation of ARPP19 and ENSA at
CC       'Ser-62' and 'Ser-67', respectively. ARPP19 and ENSA are
CC       phosphatase inhibitors that specifically inhibit the PPP2R2D
CC       (PR55-delta) subunit of PP2A. Inactivation of PP2A during M phase
CC       is essential to keep cyclin-B1-CDK1 activity high. Following DNA
CC       damage, it is also involved in checkpoint recovery by being
CC       inhibited. Phosphorylates histone protein in vitro; however such
CC       activity is unsure in vivo. May be involved in megakaryocyte
CC       differentiation. {ECO:0000269|PubMed:12890928,
CC       ECO:0000269|PubMed:19680222, ECO:0000269|PubMed:19793917,
CC       ECO:0000269|PubMed:20538976, ECO:0000269|PubMed:20818157}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:21164014}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome. Nucleus. Cleavage furrow.
CC       Note=During interphase is mainly nuclear, upon nuclear envelope
CC       breakdown localizes at the cytoplasm and during mitosis at the
CC       centrosomes. Upon mitotic exit moves to the cleavage furrow.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q96GX5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96GX5-2; Sequence=VSP_014574, VSP_014575;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q96GX5-3; Sequence=VSP_014574;
CC   -!- PTM: Phosphorylation at Thr-741 by CDK1 during M phase activates
CC       its kinase activity (By similarity). Maximum phosphorylation
CC       occurs in prometaphase. {ECO:0000250, ECO:0000269|PubMed:20538976,
CC       ECO:0000269|PubMed:20818157}.
CC   -!- DISEASE: Thrombocytopenia 2 (THC2) [MIM:188000]: Thrombocytopenia
CC       is defined by a decrease in the number of platelets in circulating
CC       blood, resulting in the potential for increased bleeding and
CC       decreased ability for clotting. {ECO:0000269|PubMed:12890928}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: Reduced levels of MASTL by RNAi causes mitotic
CC       abnormalities that consist of delay in G(2) phase and slow
CC       chromosome condensation. Cells that enter and progress through
CC       mitosis often fail to completely separate their sister chromatids
CC       in anaphase leading to the formation of 4N G(1) cells subsequent
CC       to failure of cytokinesis (PubMed:20818157 and PubMed:20538976).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK027719; BAB55321.1; -; mRNA.
DR   EMBL; AK074804; BAC11218.1; -; mRNA.
DR   EMBL; AL160291; CAI16908.1; -; Genomic_DNA.
DR   EMBL; AL160291; CAI16909.1; -; Genomic_DNA.
DR   EMBL; AL160291; CAI16910.1; -; Genomic_DNA.
DR   EMBL; BC009107; AAH09107.1; -; mRNA.
DR   CCDS; CCDS53502.1; -. [Q96GX5-1]
DR   CCDS; CCDS53503.1; -. [Q96GX5-2]
DR   CCDS; CCDS7153.1; -. [Q96GX5-3]
DR   RefSeq; NP_001165774.1; NM_001172303.2. [Q96GX5-1]
DR   RefSeq; NP_001165775.1; NM_001172304.2. [Q96GX5-2]
DR   RefSeq; NP_116233.2; NM_032844.4. [Q96GX5-3]
DR   UniGene; Hs.276905; -.
DR   PDB; 5LOH; X-ray; 3.10 A; A/B=1-194, A/B=740-879.
DR   PDBsum; 5LOH; -.
DR   ProteinModelPortal; Q96GX5; -.
DR   SMR; Q96GX5; -.
DR   BioGrid; 124364; 23.
DR   IntAct; Q96GX5; 21.
DR   STRING; 9606.ENSP00000365107; -.
DR   iPTMnet; Q96GX5; -.
DR   PhosphoSitePlus; Q96GX5; -.
DR   BioMuta; MASTL; -.
DR   DMDM; 68565604; -.
DR   EPD; Q96GX5; -.
DR   MaxQB; Q96GX5; -.
DR   PaxDb; Q96GX5; -.
DR   PeptideAtlas; Q96GX5; -.
DR   PRIDE; Q96GX5; -.
DR   DNASU; 84930; -.
DR   Ensembl; ENST00000342386; ENSP00000343446; ENSG00000120539. [Q96GX5-2]
DR   Ensembl; ENST00000375940; ENSP00000365107; ENSG00000120539. [Q96GX5-1]
DR   Ensembl; ENST00000375946; ENSP00000365113; ENSG00000120539. [Q96GX5-3]
DR   GeneID; 84930; -.
DR   KEGG; hsa:84930; -.
DR   UCSC; uc001itl.3; human. [Q96GX5-1]
DR   CTD; 84930; -.
DR   DisGeNET; 84930; -.
DR   GeneCards; MASTL; -.
DR   HGNC; HGNC:19042; MASTL.
DR   HPA; HPA027175; -.
DR   HPA; HPA054273; -.
DR   MalaCards; MASTL; -.
DR   MIM; 188000; phenotype.
DR   MIM; 608221; gene.
DR   neXtProt; NX_Q96GX5; -.
DR   OpenTargets; ENSG00000120539; -.
DR   Orphanet; 168629; Autosomal thrombocytopenia with normal platelets.
DR   PharmGKB; PA134943781; -.
DR   eggNOG; ENOG410IUCW; Eukaryota.
DR   eggNOG; ENOG410ZHM9; LUCA.
DR   GeneTree; ENSGT00530000063286; -.
DR   HOVERGEN; HBG074267; -.
DR   InParanoid; Q96GX5; -.
DR   KO; K16309; -.
DR   OMA; CAYSGSY; -.
DR   OrthoDB; EOG091G01J6; -.
DR   PhylomeDB; Q96GX5; -.
DR   TreeFam; TF313149; -.
DR   Reactome; R-HSA-2465910; MASTL Facilitates Mitotic Progression.
DR   SignaLink; Q96GX5; -.
DR   SIGNOR; Q96GX5; -.
DR   GeneWiki; MASTL; -.
DR   GenomeRNAi; 84930; -.
DR   PRO; PR:Q96GX5; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000120539; -.
DR   CleanEx; HS_MASTL; -.
DR   ExpressionAtlas; Q96GX5; baseline and differential.
DR   Genevisible; Q96GX5; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-KW.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016301; F:kinase activity; IDA:UniProtKB.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; ISS:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; ISS:UniProtKB.
DR   GO; GO:0007147; P:female meiosis II; IEA:Ensembl.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0007067; P:mitotic nuclear division; IMP:UniProtKB.
DR   GO; GO:0032515; P:negative regulation of phosphoprotein phosphatase activity; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0051441; P:positive regulation of ubiquitin-protein ligase activity involved in meiotic cell cycle; IEA:Ensembl.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:UniProtKB.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cell cycle; Cell division; Complete proteome; Cytoplasm; Cytoskeleton;
KW   Disease mutation; Kinase; Mitosis; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    879       Serine/threonine-protein kinase
FT                                greatwall.
FT                                /FTId=PRO_0000086315.
FT   DOMAIN       35    835       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      836    879       AGC-kinase C-terminal.
FT   NP_BIND      41     49       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    156    156       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      62     62       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES     207    207       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     222    222       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     293    293       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     370    370       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     453    453       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     519    519       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     552    552       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     556    556       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     631    631       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     657    657       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     668    668       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     722    722       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     725    725       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     741    741       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     875    875       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     878    878       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     708    708       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_014574.
FT   VAR_SEQ     756    793       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_014575.
FT   VARIANT     167    167       E -> D (in THC2; dbSNP:rs28941470).
FT                                {ECO:0000269|PubMed:12890928}.
FT                                /FTId=VAR_022838.
FT   VARIANT     337    337       T -> K (in dbSNP:rs36121140).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040792.
FT   VARIANT     606    606       D -> Y (in dbSNP:rs35413630).
FT                                /FTId=VAR_057103.
FT   VARIANT     610    610       V -> I (in dbSNP:rs35571315).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040793.
FT   VARIANT     620    620       P -> A (in dbSNP:rs3802526).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_022839.
FT   MUTAGEN      72     72       K->M: Hyperactive form.
FT                                {ECO:0000269|PubMed:21164014}.
FT   CONFLICT    634    634       K -> E (in Ref. 1; BAC11218).
FT                                {ECO:0000305}.
FT   CONFLICT    685    685       C -> R (in Ref. 1; BAB55321).
FT                                {ECO:0000305}.
FT   CONFLICT    731    731       A -> P (in Ref. 1; BAC11218).
FT                                {ECO:0000305}.
FT   CONFLICT    865    865       A -> T (in Ref. 1; BAB55321).
FT                                {ECO:0000305}.
FT   HELIX        32     34       {ECO:0000244|PDB:5LOH}.
FT   STRAND       35     40       {ECO:0000244|PDB:5LOH}.
FT   STRAND       48     56       {ECO:0000244|PDB:5LOH}.
FT   STRAND       58     65       {ECO:0000244|PDB:5LOH}.
FT   TURN         66     68       {ECO:0000244|PDB:5LOH}.
FT   STRAND       96     98       {ECO:0000244|PDB:5LOH}.
FT   STRAND      103    111       {ECO:0000244|PDB:5LOH}.
FT   HELIX       118    125       {ECO:0000244|PDB:5LOH}.
FT   HELIX       130    149       {ECO:0000244|PDB:5LOH}.
FT   TURN        159    161       {ECO:0000244|PDB:5LOH}.
FT   STRAND      162    164       {ECO:0000244|PDB:5LOH}.
FT   STRAND      170    172       {ECO:0000244|PDB:5LOH}.
FT   STRAND      174    177       {ECO:0000244|PDB:5LOH}.
FT   HELIX       747    750       {ECO:0000244|PDB:5LOH}.
FT   HELIX       758    773       {ECO:0000244|PDB:5LOH}.
FT   HELIX       783    792       {ECO:0000244|PDB:5LOH}.
FT   HELIX       800    802       {ECO:0000244|PDB:5LOH}.
FT   HELIX       806    815       {ECO:0000244|PDB:5LOH}.
FT   HELIX       826    830       {ECO:0000244|PDB:5LOH}.
FT   HELIX       833    835       {ECO:0000244|PDB:5LOH}.
FT   HELIX       840    845       {ECO:0000244|PDB:5LOH}.
SQ   SEQUENCE   879 AA;  97319 MW;  E6533029D1CE58B4 CRC64;
     MDPTAGSKKE PGGGAATEEG VNRIAVPKPP SIEEFSIVKP ISRGAFGKVY LGQKGGKLYA
     VKVVKKADMI NKNMTHQVQA ERDALALSKS PFIVHLYYSL QSANNVYLVM EYLIGGDVKS
     LLHIYGYFDE EMAVKYISEV ALALDYLHRH GIIHRDLKPD NMLISNEGHI KLTDFGLSKV
     TLNRDINMMD ILTTPSMAKP RQDYSRTPGQ VLSLISSLGF NTPIAEKNQD PANILSACLS
     ETSQLSQGLV CPMSVDQKDT TPYSSKLLKS CLETVASNPG MPVKCLTSNL LQSRKRLATS
     SASSQSHTFI SSVESECHSS PKWEKDCQES DEALGPTMMS WNAVEKLCAK SANAIETKGF
     NKKDLELALS PIHNSSALPT TGRSCVNLAK KCFSGEVSWE AVELDVNNIN MDTDTSQLGF
     HQSNQWAVDS GGISEEHLGK RSLKRNFELV DSSPCKKIIQ NKKTCVEYKH NEMTNCYTNQ
     NTGLTVEVQD LKLSVHKSQQ NDCANKENIV NSFTDKQQTP EKLPIPMIAK NLMCELDEDC
     EKNSKRDYLS SSFLCSDDDR ASKNISMNSD SSFPGISIME SPLESQPLDS DRSIKESSFE
     ESNIEDPLIV TPDCQEKTSP KGVENPAVQE SNQKMLGPPL EVLKTLASKR NAVAFRSFNS
     HINASNNSEP SRMNMTSLDA MDISCAYSGS YPMAITPTQK RRSCMPHQQT PNQIKSGTPY
     RTPKSVRRGV APVDDGRILG TPDYLAPELL LGRAHGPAVD WWALGVCLFE FLTGIPPFND
     ETPQQVFQNI LKRDIPWPEG EEKLSDNAQS AVEILLTIDD TKRAGMKELK RHPLFSDVDW
     ENLQHQTMPF IPQPDDETDT SYFEARNTAQ HLTVSGFSL
//
